News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Neurocrine Biosciences, Inc. NBIX highlighted the continued expansion of its commercial portfolio during its second-quarter 2026 earnings call, with management emphasizing growth from INGREZZA, CRENESSITY and the newly acquired VYKAT XR. The company also outlined upcoming clinical catalysts and its strategy to diversify beyond …
Sharemaestro market context Trend signal active 52 weeks +16.3%Guggenheim has increased its price target for Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares to $222 from $200, maintaining a Buy rating after the company's strong second-quarter results. The company reported Ingrezza sales significantly above consensus and raised its full-year 2026 Ingrezza sales guidance, driven by …
This article provides a technical analysis of NewMarket Corp (NEU), detailing its current price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and Moving Averages. It highlights that NEU's price momentum score is 4.27, suggesting suitability for range-bound swing trading …
Neurocrine Biosciences Inc. (NBIX) filed its quarterly earnings report (Form 10-Q) with the SEC, detailing its financial performance for the quarter ended June 30, 2026. Key highlights include the completion of the Soleno Therapeutics Inc. acquisition, adding VYKAT XR to its commercial portfolio, and …
Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 12-month price target of $6.57 against a current price of $1.65. While several analysts recently lowered their price targets, the general sentiment remains positive. Institutional investors hold …
Neuropace Inc (NPCE) has an institutional shareholding score of 10.00, ranking 1st out of 199 in its industry. The institutional shareholding proportion is 99.26%, showing a 7.21% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.51% of outstanding shares.
Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced …
This article first appeared on GuruFocus. Total Revenue: Over $950 million in Q2 2026, representing nearly 40% year-over-year growth. Non-GAAP EPS: $2.85 per share for the second quarter. INGREZZA Net Sales: $716 million in Q2, up 15% year-over-year, driven by record new patient additions. …
Sharemaestro market context Trend signal active 52 weeks +16.3%This article provides an overview of NeuroOne Medical Technologies Corp (NMTC), including its current stock price and market capitalization. It indicates that relevant data for the company's revenue breakdown by business segments and regions has not yet been disclosed. The page is primarily a …
This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Net income for Q2 2026 increased to $134 million, or $14.54 per share, up from …
This article provides a brief overview of NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW) financial information. It indicates that the market was closed at the time of viewing and that no trades were made, with details on financial statements, dividends, earnings, and segments available for further …
This article reports on a Form 4 filing for Neurocrine Biosciences Inc, specifically for activity on July 30th. It prominently displays the company's stock symbol NBIX and its recent percentage change in value. The content primarily consists of section headers and navigation links, with …
Neurocrine Biosciences reported strong Q2 2026 financial results, with non-GAAP earnings per share of $2.85, significantly beating analyst expectations, and revenue reaching $959.0M, an 8.0% increase over forecasts. The company's flagship product, INGREZZA, contributed $716.0M to revenue, and full-year revenue guidance was set between …
Neurocrine Biosciences (NBIX) reported $959 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 39.5%. EPS of $2.85 for the same period compares to $1.06 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $901.54 …
Sharemaestro market context Trend signal active 52 weeks +16.3%Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …
Sharemaestro market context Trend signal active 52 weeks +16.3%Contineum Therapeutics reported its second-quarter 2026 financial results, affirming key clinical development milestones for its drug candidates. The company is focusing its resources on inflammatory and fibrotic diseases, including the global Phase 2 PROPEL-IPF trial for PIPE-791 and Johnson & Johnson's completed enrollment for …
Chardan has increased its price target for ProMIS Neurosciences (PMN.TO) to $33 from $20, while reiterating a Buy rating on the stock. This adjustment reflects a more optimistic outlook on the company's future performance.
NeuroSense Therapeutics has filed a shelf registration to offer up to $150 million in various securities and a related at-the-market (ATM) program for up to $3.8 million in ordinary shares. The company, focused on neurodegenerative diseases like ALS, reported positive Phase 2b data for …
Neurocrine Biosciences Inc. (NBIX) reported Q2 adjusted earnings per share of $2.85, significantly surpassing the FactSet estimate of $1.66. The company also announced Q2 revenue of $959.0 million, exceeding the FactSet estimate of $891.2 million. The article highlights recent news related to Neurocrine Biosciences, …
NeuroOne Medical Technologies has released a white paper detailing its StereoCED(TM) platform, designed for scalable CNS drug delivery. The platform aims to streamline robotic-assisted intracranial drug delivery, addressing challenges in existing methods for cell and gene therapies. NeuroOne anticipates the device will be available …
Cantor Fitzgerald has initiated coverage on NeuroPace (NPCE.US) with a Buy rating. The firm also announced a price target of $21 for NeuroPace's stock.
Wall Street analysts expect Neurocrine Biosciences (NBIX) to post quarterly earnings of $2.26 per share in its upcoming report, which indicates a year-over-year increase of 113.2%. Revenues are expected to be $901.54 million, up 31.1% from the year-ago quarter. The consensus EPS estimate for …
Sharemaestro market context Trend signal active 52 weeks +16.3%Newmarket Corp (NEU) reported its quarterly results, showing a revenue increase to $747.09M and diluted EPS of $14.54, up from $698.51M and $11.84 respectively a year prior. Net income also rose to $133.75M. The company experienced revenue growth driven by petroleum additives price increases, …
This article provides a technical analysis of Neuropace Inc (NPCE), focusing on its support and resistance levels, key indicators, and moving averages. NPCE's current price momentum score is 4.49, and it is trading between a resistance level of 16.77 and a support level of …
This article provides a valuation analysis of Clearpoint Neuro Inc (CLPT) as of July 31, 2026. The company's valuation score is 7.11, placing it 142nd out of 199 in the Healthcare Equipment & Supplies industry. The article highlights CLPT's current P/E ratio of -14.82 …
Several biotech stocks, including Anika Therapeutics (ANIK), Chemed Corporation (CHE), ICU Medical (ICUI), Neurocrine Biosciences (NBIX), and Royalty Pharma (RPRX), reached new 52-week highs on July 29, 2026. This surge was primarily driven by strong second-quarter financial results and ongoing positive clinical research updates …
NewMarket Corp (NEU) has a risk assessment score of 7.81, placing it 20th out of 65 in the Chemicals industry. The company's beta of 0.57 indicates lower volatility compared to the S&P 500. The article details various risk metrics including maximum drawdown, volatility, Sharpe …
Search by ticker symbol or company name and select a result to open its chart.